logo
Plus   Neg
Share
Email

Avista Confirms FY19 Earnings Outlook - Quick Facts

While reporting financial results for the first quarter on Thursday, Avista Corp. (AVA) confirmed its full-year 2019 guidance for earnings per share.

For fiscal 2019, the company continues to project earnings in the range of $2.78 to $2.98 per share, which includes $1.01 per diluted share for the termination fee received from Hydro One and the payment of remaining transaction costs. This translates to adjusted earnings in the range of $1.77 to $1.97 per share

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.93 per share for the year. Analysts' estimates typically exclude special items.

Going forward, the company said it will continue to strive to reduce the regulatory timing lag and more closely align its earned returns with those authorized by 2022. To achieve this, it anticipates an annual earnings growth rate of 9 to 10 percent from 2020 to 2022 with a return to its normal 4 to 5 percent growth rate following 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
RELATED NEWS
Follow RTT